Pilz Bioscience aims to use psychedelics in the treatment of Autistic Spectrum Disorder (ADS), a neuroinflammatory condition. The company is fully owned by Nova Mentis.
From their website: “Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.“
The company will start Phase I clinical trials in Q2 2021.
- Nova Mentis Life Science Signs Agreement to Acquire 100% of Psychedelic-Focused Autism Research Company Pilz BioScience Corp. (press release, October 2020)
Topics of Interest
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates